Hepatitis Treatment News
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis Treatment News

April 24, 2015
FDA Gives Priority Status to AbbVie’s Hep C Therapy for Genotype 4
The FDA has granted priority review status to AbbVie’s ombitasvir/paritaprevir/ritonavir plus ribavirin to treat genotype 4 of hepatitis C.
April 23, 2015
Merck’s Hep C Therapy Cures 99% of Those with Kidney Disease
12 weeks of Merck’s grazoprevir and elbasvir cured hepatitis C in 99 percent of people with genotype 1 of the virus and advanced kidney disease.
April 22, 2015
Hepatitis C Treatment Costs Threaten to Cripple Prison Budgets
Treating hepatitis C among the long-term HCV-positive prison population in Rhode Island would cost nearly twice the entire annual budget for health care in the state’s correctional system.
European Liver Group Issues New Hep C Treatment Guidelines
The European Association for the Study of the Liver has issued revised guidelines for the treatment of hepatitis C.
April 20, 2015
Yearly Cost to Treat Global Hepatitis B Could Be Only $36 Per Person
Producing large generic quantities of the first-line hepatitis B therapy entecavir could translate to an annual treatment cost of just $36 per person.
April 13, 2015
Merck’s Hepatitis C Therapy Regains FDA 'Breakthrough' Status
Merck’s fixed-dose hepatitis combination tablet, grazoprevir/elbasvir, has received two “breakthrough therapy” designations from the FDA.
April 11, 2015
Cheap Antihistamine Combats Hepatitis C in Mice
An inexpensive over-the-counter allergy drug has been found to inhibit hepatitis C in mice, opening the possibility that the antihistamine may  one day become a part of the treatment arsenal.
April 08, 2015
Hep C Treatment Is Sometimes Cost-Effective for Genotypes 2 and 3
Treating people with genotypes 2 and 3 of hepatitis C is cost effective in some circumstances, including among those with cirrhosis and among treatment-experienced individuals.
April 06, 2015
Oral Hepatitis B Vaccine Made From GMO Corn Shows Promise
Genetically modified corn may yield an oral vaccine for hepatitis B that does not require refrigeration and costs under $1 to manufacture.
April 01, 2015
Risk Factors for Hep C Acquisition Among HIV-Positive Gay Men
Condomless receptive intercourse, ulcerative STIs, fisting and sharing sex toys are all linked with  acquiring hepatitis C among HIV-positive gay men.

April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
January 2008


Current Issue
Hep Stories
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis C
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
Tell us what you think
Do you have kidney disease?

Hepatitis C Reader Survey
© 2015 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.